Amalgamated Bank Sells 449 Shares of DaVita Inc. (NYSE:DVA)

Amalgamated Bank reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 4.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,583 shares of the company’s stock after selling 449 shares during the quarter. Amalgamated Bank’s holdings in DaVita were worth $1,433,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Franklin Resources Inc. boosted its position in DaVita by 134.6% during the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock worth $8,885,000 after purchasing an additional 31,502 shares during the period. FMR LLC boosted its holdings in shares of DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the period. Atom Investors LP acquired a new position in DaVita in the 3rd quarter valued at about $4,094,000. Assenagon Asset Management S.A. raised its holdings in DaVita by 201.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock valued at $11,159,000 after acquiring an additional 49,885 shares during the period. Finally, Neo Ivy Capital Management acquired a new stake in DaVita during the third quarter worth approximately $726,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DVA. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. Finally, Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, DaVita currently has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Stock Performance

DVA opened at $142.82 on Tuesday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a 52-week low of $124.78 and a 52-week high of $179.60. The firm has a market cap of $11.43 billion, a P/E ratio of 13.30, a price-to-earnings-growth ratio of 1.07 and a beta of 0.94. The business’s fifty day moving average is $160.45 and its 200-day moving average is $158.18.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.